MetaCap

OKYO Pharma (OKYO) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 49.5% versus a loss of 76.7%. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $56.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OKYO-49.53%TNYA-76.70%
+53%-15%-83%
Nov 21, 20251 yearNov 20, 2026
OKYO-64.33%TNYA-95.69%
+31%-36%-102%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OKYO versus TNYA key metrics
MetricOKYOTNYA
Share price$1.07$0.2866
Market cap$56.15M$65.32M
1-day change-7.76%-3.99%
YTD return-48.31%-59.75%
1-year return-49.53%-76.70%
5-year return—-98.50%
EPS (TTM)$-0.24$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-4.71M$-90.60M
52-week high$3.20$1.46
52-week low$1.00$0.28
Distance from 52-week high-66.56%-80.37%
Analyst consensusstrong_buynone
Avg. price target upside+678.50%+1016.54%
Average volume143.41K2.96M
Shares outstanding52.48M227.93M
Employees570
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKYO has outperformed TNYA by 27.2 percentage points over the past year.

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

OKYO vs TNYA FAQ

Which is bigger, OKYO Pharma or Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $56.15M for OKYO Pharma (OKYO).

Which stock has performed better over the past year, OKYO or TNYA?

OKYO returned -49.53% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are OKYO Pharma and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons